Recordati (REC) Q2 2024 earnings summary

Executive summary

• Net revenue for H1 2024 reached €1,185.7 million, up 13.5% year-over-year, driven by strong growth in both Specialty & Primary Care and Rare Diseases segments across all geographies.

• EBITDA rose 11.5% to €452.9 million, with a margin of 38.2%, reflecting sector-leading profitability and operating leverage despite a diluted gross margin from product mix.

• Adjusted net income increased 4.7% to €301.0 million, while reported net income declined 1.0% to €225.4 million due to higher tax rates and financial expenses.

• Free cash flow was €256.6 million, maintaining leverage just below 1.8x EBITDA pro-forma after dividend payment.

• 2024 financial targets were revised upward, reflecting strong H1 performance and continued business momentum.

Financial highlights

• Revenue grew 13.5% year-over-year to €1,185.7 million; like-for-like growth at constant exchange rates was 10.2%.

• EBITDA margin remained strong at 38.2%; adjusted net income was €301.0 million (+4.7%).

• Gross profit margin declined to 67.6% from 70.1% due to product/country mix and new product consolidation.

• SG&A expenses at 27.1% of revenue; R&D expenses at 11.7% of revenue.

• Free cash flow totaled €256.6 million, slightly below prior year due to higher interest and tax payments.

Outlook and guidance

• FY 2024 revenue guidance raised to €2,300–2,340 million, reflecting 10.5–12.4% growth.

• EBITDA margin guidance confirmed at approximately 37%; adjusted net income expected at €560–580 million.

• Mid-single-digit growth expected for Specialty & Primary Care and double-digit growth for Rare Diseases, driven by endocrinology and oncology franchises.

• 2025 revenue guidance set at above €2.4 billion, with historical organic growth in the mid-single digits.

• FX headwind for FY 2024 estimated at around -2%.